BioCentury | May 12, 2003
Finance

Ebb & Flow

For the past few years, the major focus for investors in Neurobiological Technologies (NTII) has been on its Memantine , which is marketed in Europe for Alzheimer's disease and is awaiting U.S. approval for the same...
BioCentury | May 6, 2003
Financial News

Thomas, McNerney raises first fund

Thomas, McNerney & Partners raised $216 million for its first fund, which will invest in companies of all stages in medical device, biotech and pharmaceutical sectors. The fund also will seek later-stage spinout opportunities. The...
BioCentury | Jan 22, 2002
Finance

Ebb & Flow

With three Phase III setbacks, a high profile Phase II setback and more ImClone woes hitting the tape last week, Street watchers hope the industry is simply getting its blowups out of its system early....
BioCentury | Oct 30, 2000
Finance

Living up to expectations

Toolkit companies that went public this year enjoy a robust premium on their valuations compared to more mature toolkit plays as well as profitable product companies. Indeed, comparing market cap to projected 2001 revenues, a...
BioCentury | Oct 30, 2000
Company News

ZymoGenetics board of directors update

(ZymoGenetics spun out, B5; financing, B17) ZymoGenetics Inc., Seattle, Wash. Business: Drug discovery Appointed: Jonathan Leff, managing director at E.M. Warburg, Pincus & Co. LLC; David Hirsh, Robert Wood Johnson professor and chairman of biochemistry...
BioCentury | Oct 23, 2000
Top Story

ZymoGenetics raises $150 million

Novo Nordisk (NVO) subsidiary ZymoGenetics (Seattle, Wash) raised $150 million in a private round. The move establishes ZymoGenetics , which NVO acquired in 1988, as an independent company. ZymoGenetics had operated as NVO's primary U.S. drug...
BioCentury | Jul 31, 2000
Company News

Transkaryotic board of directors update

(Lawsuit, B7; Management, B9) Transkaryotic Therapies Inc. (TKTX), Cambridge, Mass. Business: Gene/Cell therapy, Hematology, Metabolic Appointed: Jonathan Leff, managing director of E.M. Warburg, Pincus & Co. LLC WIR Staff Hematology...
BioCentury | Jul 11, 2000
Financial News

Sunesis raises $60 million

Sunesis (Redwood City, Calif.), which is developing small molecule therapeutics against protein-protein interactions or enzymes, raised $60 million in a private financing. Investors included CSFB Private Equity; International Biotechnology Trust; Lombard Odier; E.M. Warburg, Pincus;...
BioCentury | May 22, 2000
Tools & Techniques

Angiomax: Tortured path to a lot of competition

It has been a long road for Angiomax bivalirudin, a direct thrombin inhibitor derived from the leech compound hirudin. Biogen Inc. stopped development of the compound, then called Hirulog , in 1994 after a Phase III...
BioCentury | Feb 22, 2000
Company News

Eurand America Inc., Recordati SpA deal

...purchased in 1999 from American Home Products Corp. (AHP, Madison, N.J.) by Eurand management and E.M. Warburg Pincus...
Items per page:
1 - 10 of 14
BioCentury | May 12, 2003
Finance

Ebb & Flow

For the past few years, the major focus for investors in Neurobiological Technologies (NTII) has been on its Memantine , which is marketed in Europe for Alzheimer's disease and is awaiting U.S. approval for the same...
BioCentury | May 6, 2003
Financial News

Thomas, McNerney raises first fund

Thomas, McNerney & Partners raised $216 million for its first fund, which will invest in companies of all stages in medical device, biotech and pharmaceutical sectors. The fund also will seek later-stage spinout opportunities. The...
BioCentury | Jan 22, 2002
Finance

Ebb & Flow

With three Phase III setbacks, a high profile Phase II setback and more ImClone woes hitting the tape last week, Street watchers hope the industry is simply getting its blowups out of its system early....
BioCentury | Oct 30, 2000
Finance

Living up to expectations

Toolkit companies that went public this year enjoy a robust premium on their valuations compared to more mature toolkit plays as well as profitable product companies. Indeed, comparing market cap to projected 2001 revenues, a...
BioCentury | Oct 30, 2000
Company News

ZymoGenetics board of directors update

(ZymoGenetics spun out, B5; financing, B17) ZymoGenetics Inc., Seattle, Wash. Business: Drug discovery Appointed: Jonathan Leff, managing director at E.M. Warburg, Pincus & Co. LLC; David Hirsh, Robert Wood Johnson professor and chairman of biochemistry...
BioCentury | Oct 23, 2000
Top Story

ZymoGenetics raises $150 million

Novo Nordisk (NVO) subsidiary ZymoGenetics (Seattle, Wash) raised $150 million in a private round. The move establishes ZymoGenetics , which NVO acquired in 1988, as an independent company. ZymoGenetics had operated as NVO's primary U.S. drug...
BioCentury | Jul 31, 2000
Company News

Transkaryotic board of directors update

(Lawsuit, B7; Management, B9) Transkaryotic Therapies Inc. (TKTX), Cambridge, Mass. Business: Gene/Cell therapy, Hematology, Metabolic Appointed: Jonathan Leff, managing director of E.M. Warburg, Pincus & Co. LLC WIR Staff Hematology...
BioCentury | Jul 11, 2000
Financial News

Sunesis raises $60 million

Sunesis (Redwood City, Calif.), which is developing small molecule therapeutics against protein-protein interactions or enzymes, raised $60 million in a private financing. Investors included CSFB Private Equity; International Biotechnology Trust; Lombard Odier; E.M. Warburg, Pincus;...
BioCentury | May 22, 2000
Tools & Techniques

Angiomax: Tortured path to a lot of competition

It has been a long road for Angiomax bivalirudin, a direct thrombin inhibitor derived from the leech compound hirudin. Biogen Inc. stopped development of the compound, then called Hirulog , in 1994 after a Phase III...
BioCentury | Feb 22, 2000
Company News

Eurand America Inc., Recordati SpA deal

...purchased in 1999 from American Home Products Corp. (AHP, Madison, N.J.) by Eurand management and E.M. Warburg Pincus...
Items per page:
1 - 10 of 14